Gallbladder cancer may be linked to estrogens, says UH team
Further research could lead to new drugs, determining risks
"For the first time, we show in this paper that the absence of liver X beta receptors, or LXR(beta) in a complex interplay with estrogens, induces gallbladder cancer exclusively in female mice," Gustafsson said. "Interestingly, the elimination of estrogens prevents the development of tumors in this animal model."
In the study, the team found that chronic inflammatory gall bladder disease characteristic of LXR(beta)-/- mice, led to gallbladder lesions that developed and evolved into cancer in older female mice. It is known that metabolic and hormonal alterations have been associated with this invasive disease, and LXR(beta); is a sensor for cholesterol derivatives. By removing the ovaries and reducing estrogen levels, the researchers were able to prevent the development of tumors in LXR(beta)-/- mice.
There are many crucial clinical implications resulting from these findings. First, drugs that decrease the level of estrogens might be added to the conventional treatment of gallbladder cancer. And, in the long term, pharmacological activators of LXR(beta) could become potential new anti-cancer drugs that may reduce or regulate the proliferation of gallbladder cells.
Additionally, in looking at families affected by hereditary gallbladder cancers, this research could shed light upon mutations in the sequence of LXR(beta) that may be responsible for this particular cancer, indicating a higher risk for this disease. This, in turn, could one day be used to determine individual risks.
Most read news
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.